Compare · BNTX vs INKT
BNTX vs INKT
Side-by-side comparison of BioNTech SE (BNTX) and MiNK Therapeutics Inc. (INKT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BNTX and INKT operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BNTX is the larger of the two at $22.66B, about 446.7x INKT ($50.7M).
- Over the past year, BNTX is down 16.6% and INKT is down 27.8% - BNTX leads by 11.1 points.
- BNTX has been more active in the news (11 items in the past 4 weeks vs 4 for INKT).
- BNTX has more recent analyst coverage (25 ratings vs 8 for INKT).
- Company
- BioNTech SE
- MiNK Therapeutics Inc.
- Price
- $87.69-2.80%
- $10.82-6.03%
- Market cap
- $22.66B
- $50.7M
- 1M return
- -11.18%
- -13.62%
- 1Y return
- -16.64%
- -27.76%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2021
- News (4w)
- 11
- 4
- Recent ratings
- 25
- 8
BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
MiNK Therapeutics Inc.
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate includes AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.
Latest BNTX
- SEC Form 6-K filed by BioNTech SE
- BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer
- SEC Form 4 filed by BioNTech SE
- Argus initiated coverage on BioNTech
- SEC Form 4 filed by BioNTech SE
- SEC Form 4 filed by BioNTech SE
- Chief Executive Officer Sahin Ugur sold $3,301,068 worth of Ordinary Shares (34,000 units at $97.09) as part of a pre-agreed trading plan, decreasing direct ownership by 16% to 180,209 units (SEC Form 4)
- Chief Executive Officer Sahin Ugur sold $6,480,659 worth of Ordinary Shares (66,000 units at $98.19) as part of a pre-agreed trading plan, decreasing direct ownership by 24% to 214,209 units (SEC Form 4)
- Chief Executive Officer Sahin Ugur sold $6,012,500 worth of Ordinary Shares (61,000 units at $98.57) as part of a pre-agreed trading plan, decreasing direct ownership by 18% to 280,209 units (SEC Form 4)
- Chief Executive Officer Sahin Ugur sold $6,842,742 worth of Ordinary Shares (69,000 units at $99.17) as part of a pre-agreed trading plan, decreasing direct ownership by 17% to 341,209 units (SEC Form 4)
Latest INKT
- SEC Form 4 filed by MiNK Therapeutics Inc.
- SEC Form 144 filed by MiNK Therapeutics Inc.
- MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026
- MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy
- Director Wiinberg Ulf was granted 1,279 shares, increasing direct ownership by 6% to 23,929 units (SEC Form 4)
- Director Behner Peter was granted 1,485 shares, increasing direct ownership by 6% to 24,404 units (SEC Form 4)
- Director Holcomb John Bradley was granted 1,233 shares, increasing direct ownership by 36% to 4,691 units (SEC Form 4)
- Director Ryan Barbara was granted 1,622 shares, increasing direct ownership by 7% to 23,591 units (SEC Form 4)
- Director Corvese Brian was granted 1,633 shares, increasing direct ownership by 3% to 54,770 units (SEC Form 4)
- SEC Form S-8 filed by MiNK Therapeutics Inc.